Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.
Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF inhibitors, even when they respond dramatically, rapidly adapt and develop resistance. Thus, there is a pressing need to identify the major mechanisms of intrinsic and adaptive resistance and develop...
Main Authors: | Brian J Capaldo, Devin Roller, Mark J Axelrod, Alex F Koeppel, Emanuel F Petricoin, Craig L Slingluff, Michael J Weber, Aaron J Mackey, Daniel Gioeli, Stefan Bekiranov |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4583389?pdf=render |
Similar Items
-
Current Advances in the Treatment of BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2020-02-01) -
Dabrafenib for treatment of BRAF-mutant melanoma
by: Kainthla R, et al.
Published: (2013-12-01) -
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
by: Ernesto Rossi, et al.
Published: (2019-04-01) -
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
by: Spagnolo F, et al.
Published: (2015-01-01) -
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
by: Irene Vanni, et al.
Published: (2020-07-01)